Professional
Added to YB: 2024-02-20
Pitch date: 2023-12-31
ILMN [bullish]
Illumina, Inc.
+0.64%
current return
Author Info
No bio for this author
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Market Cap
$18.4B
Pitch Price
$134.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
15.81
P/E
27.05
EV/Sales
4.60
Sector
Life Sciences Tools and Services
Category
growth
Baron Focused Growth Fund Portfolio Holding - Illumina Inc.
$ILMN: Initiated position after 45% decline mainly due to Grail controversy. Diverse DNA sequencing products for research, diagnostics, cancer Rx, prenatal testing. $120B TAM vs $4.5B sales. High margins & cash flow, ramping up investments for double-digit rev growth & faster EBITDA growth. Bullish long-term.
Read full article (1 min)